Last updated: April 23, 2026
Who supplies albendazole API and what are the coverage gaps?
Albendazole supply is typically handled through two tiers: API manufacturers (including specialty generics API plants) and formulation suppliers (finished-dose makers and contract manufacturers). Supplier presence is global, but market access often hinges on whether the supplier can support DMF/ASMF traceability, regulatory documentation, and GMP compliance for the target geography.
Which regulatory supply routes matter for buyers?
For albendazole, purchasing is usually evaluated through documentation readiness, not only unit cost:
- API filing status: US DMF/EDMF, EU ASMF, and local equivalents
- GMP status: inspected sites and accepted quality agreements
- Quality specs: particle size and impurity profiles consistent across batches
- CMC support: stability, analytical methods, and change control documentation
These factors determine whether a supplier can qualify for hospital tenders, public health procurement, or regulated commercial launches.
Who are the key albendazole API supplier categories buyers should target?
Because “albendazole” is widely manufactured and sourced, the practical supplier landscape breaks into four categories:
1) Multiregional generics API manufacturers
These suppliers sell internationally and typically support multiple dossiers and customer qualification workflows. Buyers usually shortlist these suppliers for:
- predictable supply
- established DMF/ASMF documentation
- batch-to-batch consistency
2) Indian generic API suppliers
India remains a high-volume source for many benzimidazole APIs. Many suppliers offer:
- competitive pricing
- fast lead times
- broad grade availability
3) China-based API and intermediate suppliers
China supplies large volumes of generic APIs and related intermediates. Buyers evaluate:
- quality dossier completeness
- impurity and crystallization control
- inspection history
4) Contract development and manufacturing organizations (CDMOs) for finished dosage
For finished albendazole tablets and suspensions, CDMOs matter when customers need:
- formulation development and scale-up
- packaging compliance
- local market manufacturing or parallel filling
Which finished-dose suppliers are relevant to procurement?
Finished-dose albendazole is sold as tablets and in some markets as chewable tablets or suspensions, with a strong public health component. Finished-dose suppliers typically include:
- major branded and multinational generics companies
- local market manufacturers
- CDMOs producing for label holders
Procurement due diligence usually focuses on:
- bioequivalence package availability (where required)
- validated dissolution methodology
- packaging integrity and shelf-life stability data
What specific supplier deliverables should buyers require?
To avoid qualification delays, buyers typically require the following from albendazole suppliers:
- Certificates: CoA for each lot, including impurities and residual solvents where applicable
- Spec package: active content assay, impurities list, and acceptance criteria
- Regulatory dossier mapping: DMF/ASMF reference, applicant rights, and letter-of-access feasibility
- GMP evidence: current GMP inspection status for manufacturing site(s)
- Quality agreement: change notification timelines, deviation handling, and comparator materials approach
How buyers usually structure sourcing: primary vs. backup
Given albendazole’s commoditized profile, procurement often uses a dual-source model:
- Primary supplier: qualified API or finished-dose with stable supply history
- Secondary supplier: qualified “ready to switch” to reduce line risk
- Contingency terms: buffer stock requirements and expedited shipment clauses
What are the main commercial constraints in albendazole supply?
Albendazole availability is generally strong, but constraints emerge from:
- site-specific GMP suspensions or remediation cycles
- raw material availability and intermediate bottlenecks
- documentation delays for newly added suppliers to a buyer’s quality system
Key Takeaways
- Albendazole sourcing runs through API manufacturers and finished-dose/formulation suppliers, with qualification decided by DMF/ASMF readiness, GMP status, and spec control, not just price.
- Buyers typically shortlist multiregional generics API suppliers, high-volume India and China API plants, and CDMOs for finished dosage when local manufacturing or formulation support is needed.
- Procurement risk is managed with a primary plus backup supplier model backed by quality agreements, change notification terms, and documented CoA/spec support.
FAQs
1) What is the difference between buying albendazole API and finished-dose albendazole?
API supply supports CMC and manufacturing by the buyer or a CDMO. Finished-dose supply supports direct market release through the supplier’s validated formulation, packaging, and distribution systems.
2) What documentation most often gates approval for albendazole API suppliers?
Most often the buyer needs DMF/ASMF alignment, GMP inspection evidence for the site, and a spec package that matches the buyer’s acceptable impurity profile and test methods.
3) Are albendazole suppliers usually interchangeable?
Not without requalification. Even for the same labeled API, impurity profiles, crystallization behavior, and analytical method differences can require stability and process confirmation.
4) What contract terms matter most for long-lead albendazole supply?
Quality agreement terms, change control notification timelines, deviation and recall obligations, and buffer stock or expedited shipment clauses.
5) What tends to drive price changes for albendazole?
Supply disruptions at GMP sites, raw material or intermediate constraints, and documentation readiness costs tied to dossier updates and batch release requirements.
Sources
[1] European Medicines Agency (EMA). Excipients and active substance master files (ASMF) information (public regulatory materials). https://www.ema.europa.eu/
[2] U.S. Food and Drug Administration (FDA). Drug Master File (DMF) information. https://www.fda.gov/
